e-Edition
Obituaries
Special Sections
Special Occasions
Contact

Subscribe
Paywall Login
Login to Comment
Register

December 11th, 2017

jobs

homes

Home
News
Sports
Business
Entertainment
Classifieds
Commentary

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Gilead Sciences (NQ:GILD)

147.23 -4.45 (-2.93%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 10, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Gilead Sciences

< Previous 1 2 3 4 5 6 7 8 9

...

50 51 Next >

Gilead (GILD) Q4 2025 Earnings Call Transcript ↗

Today 18:05 EST

Gilead (GILD) Q4 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Gilead Stock Slips After Q4 Earnings, Weak FY26 Guidance ↗

Today 17:56 EST

Here's a look at the details inside Gilead Sciences' fourth-quarter earnings report.

Via Benzinga

Gilead Sciences’s (NASDAQ:GILD) Q4 CY2025 Sales Beat Estimates

Today 16:17 EST

Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) reported Q4 CY2025 results exceeding the market’s revenue expectations, with sales up 5.2% year on year to $7.93 billion. On the other hand, the...

Via StockStory

Topics Earnings

Will Gilead's Solid Fourth Quarter Be Enough To Shake Off Its Light Outlook? ↗

Today 16:03 EST

Gilead Sciences cleanly beat fourth-quarter expectations late Tuesday, but Gilead stock could take a hit on its light outlook.

Via Investor's Business Daily

Gilead Sciences Inc. (NASDAQ:GILD) Passes the Caviar Cruise Quality Investing Screen ↗

January 22, 2026

Via Chartmill

GILEAD SCIENCES INC (NASDAQ:GILD): A High-Yield, Low-Payout Dividend Stock for Disciplined Investors ↗

January 20, 2026

Via Chartmill

Gilead’s Second Act: A 2026 Deep Dive into the Transition from Virology to Oncology Powerhouse

Today 10:26 EST

Date: February 10, 2026 Introduction For years, Gilead Sciences, Inc. (Nasdaq: GILD) was characterized by investors as a "value trap"—a cash-rich biopharma giant that had lost its way after the...

Via Finterra

Topics Economy Intellectual Property

Should You Buy Gilead Sciences Before Feb. 10? ↗

February 09, 2026

Will the recent momentum be cut short following the biotech's Feb. 10 earnings release, or will it continue?

Via The Motley Fool

Exploring Gilead Sciences's Earnings Expectations ↗

February 09, 2026

Via Benzinga

Gilead Sciences (GILD) Reports Q4: Everything You Need To Know Ahead Of Earnings

February 08, 2026

Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) will be reporting earnings this Tuesday afternoon. Here’s what you need to know.

Via StockStory

Topics Artificial Intelligence World Trade

Here's How Much You Would Have Made Owning Gilead Sciences Stock In The Last 5 Years ↗

February 05, 2026

Via Benzinga

This Overlooked Biotech Giant Could Surprise Investors This Quarter

February 05, 2026

Investors may be underestimating the long-term potential of Gilead’s evolving portfolio.

Via Barchart.com

1 Safe-and-Steady Stock with Competitive Advantages and 2 Facing Challenges

February 02, 2026

A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on higher-reward opportunities elsewhere.

Via StockStory

Large Cap Biopharmaceuticals: A Core Position For A Healthcare Portfolio ↗

February 02, 2026

Large-cap biopharma offers stable growth and dividends, outperforming the S&P 500 in early 2026. With Gilead up 46% and Pfizer yielding 6%, the sector remains a key volatility hedge following...

Via Talk Markets

Topics Stocks

3 Cash-Producing Stocks with Warning Signs

January 29, 2026

While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak...

Via StockStory

Are Wall Street Analysts Predicting Gilead Sciences Stock Will Climb or Sink?

January 29, 2026

Gilead Sciences has outperformed the broader market over the past year, and analysts are highly optimistic about the stock’s prospects.

Via Barchart.com

Topics ETFs

Demystifying Gilead Sciences: Insights From 17 Analyst Reviews ↗

January 27, 2026

Via Benzinga

Exploring the top movers within the S&P500 index during today's session. ↗

January 23, 2026

Via Chartmill

Here's How Much $1000 Invested In Gilead Sciences 15 Years Ago Would Be Worth Today ↗

January 22, 2026

Via Benzinga

Gilead Sciences Earnings Preview: What to Expect

January 19, 2026

Gilead Sciences is expected to release its fiscal fourth-quarter earnings soon, and analysts project a decline in EPS.

Via Barchart.com

Topics Artificial Intelligence ETFs Government

Looking Into Gilead Sciences Inc's Recent Short Interest ↗

January 16, 2026

Via Benzinga

A New Era in Rare Hepatology: The Deep-Dive Analysis of Mirum Pharmaceuticals (MIRM)

January 13, 2026

Date: January 13, 2026 Introduction Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) has reached a critical inflection point, evolving from a speculative clinical-stage biotech into a commercial-stage...

Via PredictStreet

Topics Economy Initial Public Offering

J&J Cuts Deal With Trump’s White House To Slash Drug Prices And Dodge Tariffs ↗

January 08, 2026

Via Stocktwits

Topics Government

The 2026 Pharma M&A Outlook: Obesity, HIV, and the Biotech Renaissance

January 07, 2026

As the pharmaceutical industry rings in 2026, the landscape of healthcare investment has shifted from cautious recovery to a full-scale acquisition frenzy. Driven by a looming "super-cliff" of patent...

Via MarketMinute

Topics Artificial Intelligence Economy Intellectual Property

Gilead Sciences (GILD): Buy, Sell, or Hold Post Q3 Earnings?

January 05, 2026

Gilead Sciences trades at $117.95 and has moved in lockstep with the market. Its shares have returned 5.5% over the last six months while the S&P 500 has gained 10.1%.

Via StockStory

Topics Stocks

U.S. Scales Back The Number Of Vaccines It Recommends For Every Child ↗

January 05, 2026

Move comes in response to a presidential memorandum issued by President Donald Trump in December, aimed at aligning U.S. vaccination practices with other developed nations.

Via Stocktwits

Topics Government

3 Cash-Flow Machines Investors May Want Heading Into 2026 ↗

January 02, 2026

Via MarketBeat

Here's How Much $1000 Invested In Gilead Sciences 15 Years Ago Would Be Worth Today ↗

January 01, 2026

Via Benzinga

Biotech’s Resurgence: How a Year-End Rally and M&A Frenzy Set the Stage for 2026

December 31, 2025

As the final bells ring on Wall Street for 2025, the biotechnology sector is celebrating a dramatic reversal of fortune. After years of navigating high interest rates and regulatory uncertainty, the...

Via MarketMinute

Topics Artificial Intelligence ETFs Economy

The Great Rebalancing: As Consumer Confidence Falters, Investors Retreat to the Safety of Large-Cap Value

December 31, 2025

As the curtain closes on 2025, the exuberant "risk-on" sentiment that defined the early years of the artificial intelligence boom has been replaced by a somber, calculated retreat. On this final day of...

Via MarketMinute

Topics Artificial Intelligence ETFs Economy

< Previous 1 2 3 4 5 6 7 8 9

...

50 51 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

More ways to get to us

Facebook

Twitter

YouTube

ePaper Login
Subscribe
Subscription Services
Archive

About Us

The Lethbridge Herald
Other Publications
Food For Thought

Contact
Careers

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

Advertising
Terms and Conditions & Privacy Policy